Showing 4,681 - 4,700 results of 4,838 for search '(( significant decrease decrease ) OR ( significant time decrease ))~', query time: 0.37s Refine Results
  1. 4681

    <b>Concurrent initiation of treadmill exercise protects against angiotensin II-induced renal injury by modulating oxidative stress and autophagy in mice</b> by Ji-Seok Kim (21287672)

    Published 2025
    “…The 4-week AngII group exhibited significantly increased fibrosis (~2-fold vs. Veh, p < 0.01), elevated TGF-β and iNOS expression, and disrupted autophagic flux, including increased LC3-II/I ratio and ATG expression, alongside decreased p62 levels. …”
  2. 4682
  3. 4683

    Table 1_The role of serum albumin and albumin-related nutritional indices in predicting post-stroke cognitive impairment: a systematic review and meta-analysis.docx by Yan-qiu Wang (20565725)

    Published 2025
    “…We systematically searched six databases with a time frame from the date of database establishment to March 29, 2025. …”
  4. 4684

    Reactive Organic Gases from Vehicle Evaporative Emissions: Rates, Compositions, and Temperature Effects by Jun Lu (36049)

    Published 2025
    “…The emission composition shifted significantly across high-, normal-, and low-emitting vehicles: traditional hydrocarbons decreased progressively, while carbonyls/ketones increased, attenuating hydroxyl radical reactivity (OHR) reduction. …”
  5. 4685

    Data Sheet 1_Qing-Re-Hua-Shi Decoction ameliorates DSS-induced colitis by modulating multiple signaling pathways and remodeling the gut microbiota and metabolite profile.pdf by Wei Chen (23863)

    Published 2025
    “…</p>Results<p>UPLC-Q-TOF/MS identified 55 compounds in QRHSD. QRHSD significantly reduced clinical activity, histological changes, and inflammatory factors in UC mice, regulated Th17/Treg balance, and enhanced intestinal barrier integrity. 16S rRNA analysis showed that QRHSD altered gut microbiota composition, increasing beneficial bacteria (e.g., Lactobacillus) and decreasing harmful bacteria (e.g., Morganella). …”
  6. 4686

    Image 4_Temporal left ventricular ejection fraction variations and outcomes in wide population of cardiovascular patients with and without heart failure.tif by Radosław Szczerba (20837081)

    Published 2025
    “…In patients with HF, Kaplan–Meier survival curves showed significantly lower MACCE occurrence in HFimpEF and stable LVEF than in decreased LVEF (11.46%/year vs. 12.5%/year vs. 21.6%/year; log-rank p = 0.199 and p < 0.001) and HFimpEF constituted one of independent predictors of MACCE (HR = 0.84, 95% CI: 0.76–0.93). …”
  7. 4687

    Table 1_Working like a mule? The physiological toll of heavy loads on mules.docx by Tamara Tadich (17244898)

    Published 2025
    “…Linear mixed models were applied to evaluate the effects of load, time, and body size.</p>Results<p>The size of the mule did not have an effect on their physiological response to work. …”
  8. 4688

    Data Sheet 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and... by Zachary D. Wallen (19986522)

    Published 2024
    “…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”
  9. 4689

    Table 4_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

    Published 2024
    “…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”
  10. 4690

    Table 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

    Published 2024
    “…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”
  11. 4691

    Table 1_Ten-year outcomes of repeat keratoplasty for optical indications.docx by Victoria Grace Dimacali (20597690)

    Published 2025
    “…Cox multiple regression analysis showed male gender (p = 0.023), PK regraft (p = 0.003), regraft rejection (p = 0.003), and initial graft indications of pseudophakic bullous keratopathy (p = 0.005) and aphakic bullous keratopathy (p = 0.004) to be risk factors for regraft failure, while longer time to regraft was associated with decreased risk of failure (p = 0.013).…”
  12. 4692

    Table 5_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

    Published 2024
    “…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”
  13. 4693

    Image 1_Ten-year outcomes of repeat keratoplasty for optical indications.png by Victoria Grace Dimacali (20597690)

    Published 2025
    “…Cox multiple regression analysis showed male gender (p = 0.023), PK regraft (p = 0.003), regraft rejection (p = 0.003), and initial graft indications of pseudophakic bullous keratopathy (p = 0.005) and aphakic bullous keratopathy (p = 0.004) to be risk factors for regraft failure, while longer time to regraft was associated with decreased risk of failure (p = 0.013).…”
  14. 4694

    Table 2_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

    Published 2024
    “…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”
  15. 4695

    Table 5_Ten-year outcomes of repeat keratoplasty for optical indications.docx by Victoria Grace Dimacali (20597690)

    Published 2025
    “…Cox multiple regression analysis showed male gender (p = 0.023), PK regraft (p = 0.003), regraft rejection (p = 0.003), and initial graft indications of pseudophakic bullous keratopathy (p = 0.005) and aphakic bullous keratopathy (p = 0.004) to be risk factors for regraft failure, while longer time to regraft was associated with decreased risk of failure (p = 0.013).…”
  16. 4696

    Table 2_Ten-year outcomes of repeat keratoplasty for optical indications.docx by Victoria Grace Dimacali (20597690)

    Published 2025
    “…Cox multiple regression analysis showed male gender (p = 0.023), PK regraft (p = 0.003), regraft rejection (p = 0.003), and initial graft indications of pseudophakic bullous keratopathy (p = 0.005) and aphakic bullous keratopathy (p = 0.004) to be risk factors for regraft failure, while longer time to regraft was associated with decreased risk of failure (p = 0.013).…”
  17. 4697

    Table 3_Ten-year outcomes of repeat keratoplasty for optical indications.docx by Victoria Grace Dimacali (20597690)

    Published 2025
    “…Cox multiple regression analysis showed male gender (p = 0.023), PK regraft (p = 0.003), regraft rejection (p = 0.003), and initial graft indications of pseudophakic bullous keratopathy (p = 0.005) and aphakic bullous keratopathy (p = 0.004) to be risk factors for regraft failure, while longer time to regraft was associated with decreased risk of failure (p = 0.013).…”
  18. 4698

    Image 2_Temporal left ventricular ejection fraction variations and outcomes in wide population of cardiovascular patients with and without heart failure.tif by Radosław Szczerba (20837081)

    Published 2025
    “…In patients with HF, Kaplan–Meier survival curves showed significantly lower MACCE occurrence in HFimpEF and stable LVEF than in decreased LVEF (11.46%/year vs. 12.5%/year vs. 21.6%/year; log-rank p = 0.199 and p < 0.001) and HFimpEF constituted one of independent predictors of MACCE (HR = 0.84, 95% CI: 0.76–0.93). …”
  19. 4699

    Table 4_Ten-year outcomes of repeat keratoplasty for optical indications.docx by Victoria Grace Dimacali (20597690)

    Published 2025
    “…Cox multiple regression analysis showed male gender (p = 0.023), PK regraft (p = 0.003), regraft rejection (p = 0.003), and initial graft indications of pseudophakic bullous keratopathy (p = 0.005) and aphakic bullous keratopathy (p = 0.004) to be risk factors for regraft failure, while longer time to regraft was associated with decreased risk of failure (p = 0.013).…”
  20. 4700

    Image 3_Temporal left ventricular ejection fraction variations and outcomes in wide population of cardiovascular patients with and without heart failure.tif by Radosław Szczerba (20837081)

    Published 2025
    “…In patients with HF, Kaplan–Meier survival curves showed significantly lower MACCE occurrence in HFimpEF and stable LVEF than in decreased LVEF (11.46%/year vs. 12.5%/year vs. 21.6%/year; log-rank p = 0.199 and p < 0.001) and HFimpEF constituted one of independent predictors of MACCE (HR = 0.84, 95% CI: 0.76–0.93). …”